Literature DB >> 17147692

Osteoprotegerin plasma levels are strongly associated with polymorphisms in human homologue of the mouse progressive ankylosis (ANKH) gene.

Y Vistoropsky1, I Malkin, E Kobyliansky, G Livshits.   

Abstract

Osteoprotegerin inhibits osteoclastogenesis and plays an important role in the control of bone resorption. However, the genetic mechanisms underlying regulation of OPG levels are currently not fully elucidated. The aim of the present study was to determine whether the ANKH gene, which plays a central role in bone mineralization, contributes to the genetic regulation of OPG levels. A family-based association study used a sample of 159 ethnically homogeneous nuclear families, comprising 556 apparently healthy individuals. Statistical analyses included family aggregation analysis of OPG variation and four types of transmission disequilibrium tests. Each individual was genotyped for 11 SNPs in the ANKH gene. Four TDTs consistently showed a highly significant association between OPG levels and the intronic SNP rs875525 located between exons 6 and 7. The combined p-value for four tests to reject the null hypothesis of no association was 0.0003. Furthermore, haplotypes generated between rs875525 and two additional neighbouring SNPs (rs2291943 and rs2288474) also revealed a significant association with OPG plasma levels (p < 10(-4)-10(-3)). ANKH genetic polymorphisms in the area between SNP rs2291943 and rs2288474 are strongly associated with OPG plasma levels. The molecular mechanism underlying this association is not obvious, and therefore these results should be regarded cautiously until they are confirmed in independent studies.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17147692     DOI: 10.1111/j.1469-1809.2006.00331.x

Source DB:  PubMed          Journal:  Ann Hum Genet        ISSN: 0003-4800            Impact factor:   1.670


  4 in total

1.  Hip geometry variation is associated with bone mineralization pathway gene variants: The Framingham Study.

Authors:  Ching-Lung Cheung; Gregory Livshits; Yanhua Zhou; James B Meigs; Jarred B McAteer; Jose C Florez; L Adrienne Cupples; Serkalem Demissie; Douglas P Kiel; David Karasik
Journal:  J Bone Miner Res       Date:  2010-07       Impact factor: 6.741

2.  Meta-analysis of genome-wide association studies identifies two loci associated with circulating osteoprotegerin levels.

Authors:  Johnny S H Kwan; Yi-Hsiang Hsu; Ching-Lung Cheung; Josée Dupuis; Aude Saint-Pierre; Joel Eriksson; Samuel K Handelman; Aaron Aragaki; David Karasik; Peter P Pramstaller; Charles Kooperberg; Andrea Z Lacroix; Martin G Larson; Kam-Shing Lau; Mattias Lorentzon; Irene Pichler; Pak C Sham; Daniel Taliun; Liesbeth Vandenput; Douglas P Kiel; Andrew A Hicks; Rebecca D Jackson; Claes Ohlsson; Emelia J Benjamin; Annie W C Kung
Journal:  Hum Mol Genet       Date:  2014-07-30       Impact factor: 6.150

Review 3.  Genetic factors in the pathogenesis of CPPD crystal deposition disease.

Authors:  Ana Rita Couto; Matthew A Brown
Journal:  Curr Rheumatol Rep       Date:  2007-06       Impact factor: 4.686

Review 4.  Delineating the role of osteoprotegerin as a marker of breast cancer risk among women with a BRCA1 mutation.

Authors:  Sarah Sohyun Park; Aleksandra Uzelac; Joanne Kotsopoulos
Journal:  Hered Cancer Clin Pract       Date:  2022-04-13       Impact factor: 2.857

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.